NO_2, $XNHR^4$, $XNR^4R^{4'}$, $XNHSO_2R^4$, $XN(SO_2R^4)SO_2R^{4'}$, $XNR^4SO_2R^{4'}$, R^4, whereby two substituents at **R^2**, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl.

4. Benzimidazoles according to claim 1, wherein

R^3 means one or two substituents, which, independently of one another, can be: hydrogen, F, Cl, Br,
XOH, XOR^4, $XOCOR^4$, $XOCONHR^4$, $XOCOOR^4$,
$XCOR^4$, $XC(NOH)R^4$, $XC(NOR^4)R^{4'}$, $XC(NO(COR^4))R^{4'}$,
XCN, XSR^4, $XSOR^4$, XSO_2R^4, SO_2NH_2, SO_2NHR^4, $SO_2NR^4R^{4'}$,
NO_2, XNH_2, $XNHR^4$, $XNR^4N^{4'}$,
$XNHSO_2R^4$, $XNR^4SO_2R^{4'}$, $XN(SO_2R^4)SO_2R^{4'}$,
$XNHCOR^4$, $XNHCOOR^4$, $XNHCONHR^4$, or R^4, whereby two substituents **R^3**, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, or butane-1,4-diyl.

5. Benzimidazoles according to claim 1, wherein

R^4 and **$R^{4'}$**, independently of one another, mean CF_3, C_2F_5, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkinyl, C_{3-6} cycloalkyl, (C_{1-3} alkyl-C_{3-6} cycloalkyl), phenyl or 5- to 6-membered heteroaryl with 1-2 N, S or O atoms, whereby the phenyl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br, CH_3, C_2H_5, OCH_3, OC_2H_5, CF_3, C_2F_5,

and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C_{1-3} alkyl or C_{1-3} alkanoyl.

6. Benzimidazoles according to claim 1, wherein

R^5 and $R^{5'}$, independently of one another, can be C_{1-6} alkyl,

whereby a carbon atom can be exchanged for O, NH, N C_{1-3} alkyl, N C_{1-3} alkanoyl,

C_{3-7} cycloalkyl-C_{0-3} alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C_{1-3} alkyl or C_{1-3} alkanoyl, whereby the mentioned C_{1-6} alkyl part can be substituted with one of the previously mentioned cycloalkyls or else a 5- to 6-membered heteroaromatic compound with 1-2 heteroatoms, selected from N, S or O, whereby all previously mentioned alkyl and cycloalkyl parts can be substituted with up to two substituents that consist of CF_3, OH, O C_{1-3} alkyl, and the previously mentioned heteroaryl groups with one or two substituents that consist of F, Cl, CF_3, CH_3, C_2H_5, OCH_3, OC_2H_5, or R^5 and $R^{5'}$ together with the nitrogen atom form a 5- to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with C_{1-4} alkyl, C_{1-4} alkoxy-C_{0-2} alkyl, C_{1-4} alkoxy-carbonyl, aminocarbonyl or phenyl.

Sub C3 cont.

7. Benzimidazoles according to claim 1, wherein

A means C_{1-10} alkanediyl, C_{2-10} alkenediyl, C_{2-10} alkinediyl, (C_{0-5} alkanediyl-C_{3-7} cycloalkanediyl-C_{0-5} alkanediyl), whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, or in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C_{1-3} alkyl or C_{1-3} alkanoyl, whereby in the above-mentioned aliphatic chains, a carbon atom or two carbon atoms can be exchanged for O, NH, N C_{1-3} alkyl, or N C_{1-3} alkanoyl.

8. Benzimidazoles according to claim 1, wherein

B means COOH, $COOR^5$, $CONH_2$, $CONHR^5$, $CONR^5R^{5'}$, CONHOH, $CONHOR^5$ or tetrazolyl,

in each case bonded to a carbon atom of group **A**.

9. Benzimidazoles according to claim 1, wherein

X means a bond or methylene.

10. Benzimidazoles according to claim 1, wherein

Y means O.

12. 6-[[2-Phenyl-1-(3-pyridyl)-1H-benzimidazol-5-yl]oxy]hexanoic acid methyl ester

6-[[2-phenyl-1-(3-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-phenyl-1-(4-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(4-fluoro-phenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(4-methoxyphenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]-hexanoic acid methyl ester

6-[[2-(4-bromophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-[4-(trifluoromethyl)phenyl]-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-phenyl-2-(benzothien-2-yl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-phenyl-2-(benzothien-2-yl)-1H-benzimidazol-6-yl]oxy]hexanoic acid

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid

6-[[5-methoxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid isopropyl ester

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-methoxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

Sub C5 cont.

6-[[5-[[(4-chlorophenyl)sulfonyl]amino]-1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[[(4-chlorophenyl)sulfonyl]amino]-2-(4-fluorophenyl)-1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-(4-methoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

4-[[5-[[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]butanoic acid methyl ester

5-[[5-[[(4-chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester

5-[[5-[[(4-chlorophenyl)sulfonyl]amino]-1,2-diphenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester

6-[[5-[[(4-(trifluoromethyl)phenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[[(4-chlorophenyl)sulfonyl]methylamino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid

6-[[1-(3-fluorophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(4-nitrophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-phenyl-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

N-(cyclopropylmethoxy)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isobutoxy-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(cyclopropylmethoxy)-6-[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl)oxy]-hexanamide

N-isobutoxy-6-[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl)oxy]hexanamide

N-(2-methoxyethyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(3-methoxypropyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isobutyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-1-morpholin-1-ylhexan-1-one

N,N-di(-2-methoxyethyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isopentyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(pyridin-2-yl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(pyridin-3-yl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isopropyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N,N-dimethyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N,N-diethyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-isobutyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-cyclopropyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-cyclobutyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-**tert**-butyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

(R)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]1-(2-methoxymethyl)-pyrrolidin-1-ylhexan-1-one

N-(3-imidazol-1-yl-propyl)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-(2-pyridin-2-ylethyl)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-(3-methoxypropyl)-6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]heptanamide

6-[[1-(4-methylphenyl)-2-(3-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(4-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(3-indolyl)-1-(4-methylphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(2-furyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(3-furyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(5-methyl-2-thienyl)-1H- benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(3-methyl-2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester,

each a compound of claim 1.

13. Use of a compound according to claim 1 for the production of a pharmaceutical agent for treating or preventing diseases that are associated with a microglia activation.

14. Pharmaceutical agent, wherein it contains one or more compounds according to claim 1 and one or more vehicles.

17. Use according to claim 15, whereby in general formula II,

R^2 means a monocyclic or bicyclic aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-2 heteroatoms selected from the group that consists of N, S or O, whereby the mentioned aryl group or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:

F, Cl, Br, XOH, XOR^4, $XOCOR^4$, $XOCONHR^4$, $XOCOOR^4$, $XCOR^4$, $XC(NOH)R^4$, $XC(NOR^4)R^{4'}$, $XC(NO(COR^4))R^{4'}$, XCN, XCOOH, $XCOOR^4$, $XCONH_2$, $XCONR^4R^{4'}$, $XCONHR^4$, XCONHOH, $XCONHOR^4$, $XCOSR^4$, XSR^4, $XSOR^4$, XSO_2R^4, SO_2NH_2, SO_2NHR^4, $SO_2NR^4R^{4'}$, NO_2, XNH_2, $XNHR^4$, $XNR^4R^{4'}$, $XNHSO_2R^4$, $XN(SO_2R^4)(SO_2R^{4'})$, $XNR^4SO_2R^{4'}$, $XNHCOR^4$, $XNHCOOR^4$, $XNHCONHR^4$, R^4,

whereby two substituents at R^2, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl.

18. Use according to claim 15, whereby in general formula II

R^3 stands for one or two substituents, which independently of one another, mean:

hydrogen,

F, Cl, Br, XOH, XOR^4, $XOCOR^4$, $XOCONHR^4$, $XOCOOR^4$, $XCOR^4$, $XC(NOH)R^4$, $XC(NOR^4)R^{4'}$, $XC(NO(COR^4))R^{4'}$, XCN, XSR^4, $XSOR^4$, XSO_2R^4, SO_2NH_2, SO_2NHR^4, $SO_2NR^4R^{4'}$, NO_2, XNH_2, $XNHR^4$, $XNR^4R^{4'}$, $XNHSO_2R^4$, $XNR^4SO_2R^{4'}$, $XN(SO_2R^4)(SO_2R^{4'})$, $XNHCOR^4$, $XNHCOOR^4$, $XNHCONHR^4$, or R^4, whereby two substituents R^3, if they are in ortho-position to one another, can be linked to one another

in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl.

19. Use according to claim 15, whereby in general formula II

R^4 and $R^{4'}$, independently of one another, mean CF_3, C_2F_5, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkinyl, C_{3-6} cycloalkyl, (C_{1-3} alkyl-C_{3-6} cycloalkyl), C_{1-3} alkylaryl, C_{1-3} alkylheteroaryl, monocyclic aryl or 5- to 6-membered heteroaryl with 1-2 N, S or O atoms, whereby the aryl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br, CH_3, C_2H_5, NO_2, OCH_3, OC_2H_5, CF_3, C_2F_5 or else can carry an annelated methanediylbisoxy or ethane-1,2-diylbisoxy group, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C_{1-3} alkyl or C_{1-3} alkanoyl.

20. Use according to claim 15, whereby in general formula II

R^5 and $R^{5'}$, independently of one another, can be C_{1-6} alkyl,

whereby a carbon atom can be exchanged for O, NH, N C_{1-3} alkyl, N C_{1-3} alkanoyl, C_{3-7} cycloalkyl-C_{0-3} alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C_{1-3} alkyl or C_{1-3} alkanoyl, whereby the mentioned C_{1-6} alkyl part can be substituted with one of the previously mentioned cycloalkyls or else a 5- to 6-membered heteroaromatic compound with 1-2 heteroatoms, selected from the group that consists of N, S or O,

whereby all previously mentioned alkyl and cycloalkyl parts can be substituted with up to two substituents that consist of CF_3, OH, O C_{1-3} alkyl, and the previously mentioned heteroaryl groups can be substituted with one or two substituents that consist of F, Cl, CF_3, CH_3, C_2H_5, OCH_3, OC_2H_5,

or R^5 and $R^{5'}$ together with the nitrogen atom form a 5- to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with C_{1-4} alkyl, C_{1-4} alkoxy-C_{0-2} alkyl, C_{1-4} alkoxy-carbonyl, aminocarbonyl or phenyl.

21. Use according to claim 15, whereby in general formula II

A means C_{1-10} alkanediyl, C_{2-10} alkenediyl, C_{2-10} alkinediyl, (C_{0-5} alkanediyl-C_{3-7} cycloalkanediyl-C_{0-5} alkanediyl), or (C_{0-5} alkanediyl-heteroarylene-C_{0-5} alkanediyl), whereby an optionally present heteroaryl group can be substituted with one or two substituents that consist of F, Cl, Br, CH_3, C_2H_5, NO_2, OCH_3, OC_2H_5, CF_3, C_2F_5, and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C_{1-3} alkyl or C_{1-3} alkanoyl, whereby in an aliphatic chain, a carbon atom or two carbon atoms can be exchanged for O, NH, N C_{1-3} alkyl, N C_{1-3} alkanoyl, NSO_2 C_{1-3} alkyl, and whereby alkyl or cycloalkyl parts can be substituted with up to two F atoms or one of the substituents that consists of OH, O C_{1-3} alkyl, O C_{1-3} alkanoyl, =O, NH_2, NH C_{1-3} alkyl, N (C_{1-3} alkyl)$_2$, NH C_{1-3} alkanoyl, N (C_{1-3} alkyl) (C_{1-3} alkanoyl), NHCOO C_{1-3} alkyl, NHCONH C_{1-3} alkyl, $NHSO_2$ C_{1-3} alkyl, SH, S C_{1-3} alkyl.

22. Use according to claim 15, whereby in general formula II

B means hydrogen, OH, $OCOR^5$, $OCONHR^5$, $OCOOR^5$, COOH, $COOR^5$, $CONH_2$, $CONHR^5$, $CONR^5R^{5'}$, CONHOH, $CONHOR^5$, or tetrazolyl, in each case bonded to a carbon atom of group **A**.

23. Use according to claim 15, whereby in general formula II,

X means a bond or CH_2.

24. Use according to claim 15, whereby in general formula II,

Y means a bond, O, S, NH, NR^4, $NCOR^4$ or NSO_2R^4.